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INTRODUCTION
Gene therapy approaches for cancer have been gaining increasing 
clinical adoption and impact.1 Delivery of therapeutic genes has typ-
ically been approached through utilizing viral vectors with the vast 
majority of clinical trials, to date, involving the use of viral vectors.2,3 
Generally, viral vectors can provide efficient gene transfer, but there 
are still some disadvantages, such as the potential for toxicity asso-
ciated with chronic overexpression or insertional mutagenesis and 
the possibility of nonspecific inflammatory response and antivector 
cellular immunity.4–6 Other approaches such as using plasmid DNA 
have received less attention due in part to the weaker levels of gene 
expression achieved relative to viral systems.1,7 There are neverthe-
less several limitations, which must be considered including: toxic-
ity, long-term uncontrolled expression, chromosomal integration, 
immune response generation, and subsequent efficacy of repeat 
treatment.8 Nonviral approaches with plasmid DNA offer poten-
tial advantages for clinical application particularly as they offer a 
reduced risk profile and a simplified preparation process.
DNA plasmid vectors can allow the transfer of significantly larger 
genetic material, than is possible using a viral system; are less expen-
sive to manufacture; are considered safe, nontoxic, and less immu-
nogenic than viral vectors; and allow repeat dosing, if required.7,9–11 
However, plasmid DNA vectors can often have lower expression 
profiles than viruses and therefore lack potency in human clinical 
trials.12 Ultimately, for efficacy in gene therapy, the plasmid must 
reliably express the gene of interest at adequate levels in the target 
cell.11,12
The technology of electroporation has been employed effectively 
in both preclinical and clinical settings for the delivery of plasmid 
DNA.13–15 It has also been used to enable the uptake by passive dif-
fusion of specific chemotherapeutic drugs, with very high reported 
antitumor efficacy and negligible side effects.15–18 The process of 
electroporation involves the delivery of a microsecond pulse directly 
to the targeted tissue, which increases the local porosity of the tis-
sue to macromolecules.19 Electroporation has been established 
as a safe and effective method clinically with excellent responses 
observed in several cancer gene therapy studies. Therapies such 
as the electroporation delivery of plasmid DNA encoding for inter-
leukin-12 and antiangiogenic metargidin peptide have advanced 
to clinical trials.20,21 While electroporation facilitates the cytoplas-
mic absorption of plasmid DNA, it still lags behind viral methods 
for inducing a high degree of exogenous mRNA expression in the 
target cells. Therefore, it is important to establish and refine meth-
ods to improve electroporation-based gene delivery for clinical use. 
Optimizing strategies include modulation of electric field strength 
and pulse duration to enhance plasmid delivery, alteration of the 
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Nonviral plasmid DNA gene therapy represents a promising approach for the treatment of many diseases including cancer. Intracel-
lular delivery of DNA can be achieved with the application of electroporation, which facilitates the initial transport of exogenous 
DNA across the cell membrane into the cytoplasm. However, it does not guarantee further transport of the DNA from the cyto-
plasm to the nucleus for subsequent mRNA expression, resulting in varying degrees of exogenous gene translation and a major 
limitation in comparison to viral approaches. To overcome these expression difficulties, we developed a proof-of-concept vector 
enhanced expression vector (EEV), which incorporates elements from viral systems including nuclear localization sequences and 
a viral replicase from the Semliki Forest virus. The replicase allows for cytoplasmic mRNA expression and bypasses the need for 
nuclear localization to generate high levels of gene expression. We have demonstrated that our EEV is capable of achieving high 
levels of expression in a variety of tissue types. Antitumor effects of pEEV were demonstrated by the delayed growth and increased 
survival of the nontherapeutic pEEV-treated CT26 tumor model. Using a novel endoscopic electroporation system, EndoVe, we 
demonstrate and compare, for the first time, both standard cytomegalovirus (CMV) promoter-driven plasmid and EEV gene expres-
sion in intraluminal porcine tissues. Our EEV plasmid displays reliable and superior expression capability, and due to its inherent 
induced oncolytic activity in transfected cells, it may enhance the efficacy and safety of several cancer immunogene therapy 
approaches.
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extracellular matrix with enzymatic and chemical methods, and the 
introduction of reactive oxygen species inhibitors to reduce plas-
mid DNA destruction by reactive oxygen species generation post-
electroporation.22–26 All have an impact on increased transfer and 
gene expression efficiency via electroporation.
Viruses ensure expression of their genome within an infected 
cell by expressing a copy of their own replicase, which can tran-
scribe copies of its viral genome within the cytoplasm. In general, 
the major concern for using virus as an expression vector is their 
infective nature, which involves biological risks.8 However, the uti-
lization of replication-deficient viral vectors such as Semliki Forest 
virus (SFV) avoids this problem while allowing rapid and high-
level gene delivery.8 The SFV is a positive-stranded RNA virus of 
the genus Alphavirus of the family Togaviridae.27,28 It is a relatively 
simple virus, encoding only nine functional proteins of unique 
sequence. The SFV replicon is a eukaryotic expression vector that 
includes the cis-acting sequence for 5′ and 3′ ends of the virus 
genome and all the nonstructural proteins, with the virus struc-
tural proteins replaced by the foreign gene.29,30 By utilizing a DNA 
replicase copy from the SFV and incorporating nuclear localiza-
tion sequences to facilitate initial nuclear localization of the pEEV 
and replicase expression, we have been able to overcome some 
of the drawbacks that have hindered the application of nonviral 
approaches to cancer gene therapy.
In this study, we sought to deliver a nonviral vector system that 
has the potential for clinical application in electroporation-based 
gene therapy. We report a proof-of-concept enhanced expression 
vector (pEEV), which encompasses a viral replicase from the SFV. 
We aimed to improve upon nuclear entry by the incorporation of 
a nuclear localization sequence. We demonstrated cytoplasmic 
expression of the vector. We also investigated the oncolytic capa-
bilities of the EEV. Furthermore, we compared expression levels of 
the pEEV with standard available plasmids in murine and porcine 
animal models.
ReSUlTS
Construction of pEEV
The EEV construct consists of the cytomegalovirus (CMV) IE/T7 
promoter and SV40 polyadenylation (pA) (Figure 1). It includes the 
entire SFV capsid gene, which functions as a self-cleaving trans-
lation enhancer, an Ori colE1 (Ori) and capsid (CAP) gene. It also 
includes the SFV 1–4 nonstructural components and an ampicil-
lin resistance cassette. To this, an expanded multiple cloning site 
was incorporated for the inclusion of foreign transcripts. For our 
study, the lacZ transcript was incorporated. A nuclear localization 
sequence: CACATAACGGGAGGGCCGGCGGTTACCAGGTCGACG-
GATATGACGGCAGG was inserted to allow for better transport in 
the nucleus.
Comparison of pEEV-lacZ to standard pCMV-lacz
The EEV plasmid (15.462 kb) is approximately three times larger, 
than the standard pCMV plasmid (6.233 kb), which could impact on 
transfection efficacy and expression. To establish this, we compared 
the transfection efficiency in vivo of pEEV with the pCMV plasmid. 
In order to determine efficiency, copy numbers of each plasmid 
expressing the lacZ transgene delivered by electroporation were 
measured. Both plasmids were detected in all the tissues tested. 
In general, they were significantly more (P < 0.001) copies of pCMV 
than pEEV (Figure 2a), with the spleen and tumor having highest 
plasmid transfection.
To evaluate expression, quantitative polymerase chain reaction 
(qPCR) was used to detect lacZ transgene expression (as a reporter 
system (Figure 2b). Transgene expression from the pEEV was signifi-
cantly higher (P < 0.0001), and on average fourfold higher, than the 
respective pCMV plasmid. Taken together, these data indicate that 
high expression is achieved via an active vector, where, although 
present in fewer copies, pEEV allows an enhanced expression profile 
over the standard pCMV.
Demonstration of cytoplasmic expression of luciferase
The process for transcription of exogenous DNA material requires 
its translocation from the cytoplasm to the nucleus. The transcribed 
mRNA is then transported out of the nucleus for protein synthesis. 
Given that pEEV contains its own replicase, translation of the EEV-
reported gene could occur within the cytoplasm. To assess the 
functionality of pEEV in a cell-free assay, we used the functional 
activity of mRNA encoding T7 RNA polymerase, combined with the 
luciferase reporter gene. Luciferase expression from two plasmid 
constructs, the standard pCMV plasmid and pEEV, were compared 
(Figure 3). We could only detect pEEV-driven luciferase expression 
during this assay. These data confirmed the ability of pEEV to self-
express within the cell cytoplasm.
Cytolytic activity of pEEV
In our construction of pEEV, we utilized components of the SFV, and 
we therefore hypothesized that the nonviral pEEV may delay tumor 
growth due to excessive gene expression inducing oncolytic activ-
ity and leading to cell lysis of transfected cells. We transfected pEEV 
in an established tumor model to determine antitumor activity in 
vivo. In growing CT26 tumors, pEEV lacZ, pEEV backbone, pCMV 
lacZ, and pMG backbone were transfected by electroporation, 
and growth and survival rates were examined and compared to its 
respective untreated CT26 tumor. The nontherapeutic bearing pEEV 
significantly (P < 0.05) reduced tumor volume when compared to 
the untreated tumor (Figure 4a). Furthermore, we also observed 
improved survival of animal’s transfected with nontherapeutic 
pEEV. Interestingly, these collective data indicate that nontherapeu-
tic pEEV can improve survival rates, which may be due to the onco-
lytic effect of pEEV lacZ (Figure 4b).
To further demonstrate the oncolytic effect of nonviral pEEV, we 
transfected muscle of MF1-nu/nu mice and C57BL/6 with pCMV 
luciferase and pEEV luciferase (Figure 4c). Bioluminescent imaging 
revealed peak luciferase expression for pCMV at day 2 and day 6 for 
pEEV. pEEV expression was no longer detected by day 9, whereas 
Figure 1  Plasmid construct. Schematic representation of the circular enhanced expression vector (EEV) plasmid constructed for this study. The circular 
pEEV construct incorporates a CMV IE/T7 promoter, an Semliki Forest virus (SFV) replicase (nonstructural proteins 1–4), nuclear localization sequence, 
the entire SFV capsid gene, which functions as a self-cleaving translation enhancer, an Ori colE1 (Ori), 26S subgenomic promoter, capsid (CAP) gene 
and an ampicillin resistance cassette (AmpR).
NLS
CMVp 26S
Nonstructural proteins 1–4 Cap LacZ SV40pA Ori AmpR
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pCMV expression continued to be detected at low levels up until 
day 100. This quenching in luciferase expression of pEEV suggests 
cell lysis due to the oncolytic effect of pEEV lacZ.
Quantification of apoptosis
To assess the ability of pEEV vector in inducing apoptosis, we ana-
lyzed in vivo electroporated CT26 tumors for terminal deoxynucleo-
tidyl transferase–mediated deoxyuridine triphosphate nick-end 
labeling (TUNEL) staining. TUNEL staining shown in Figure 5 shows 
that pEEV lacZ electroporation tumors were abundant in apoptotic 
nuclei, with double-strand DNA breaks, which are hallmarks of 
apoptosis. Notably, pCMV-treated tumors did not have any TUNEL 
staining (i.e., apoptosis). These data further confirm the oncolytic 
effect of pEEV.
β-Galactosidase expression in a large animal model
Previous studies have indicated that DNA vaccines are often less 
effective in large animals when compared to responses induced in 
mice. Translation of plasmid expression into patients is essential for 
any therapeutic potential to be established. To determine if pEEV 
had this potential, we tested the plasmid expression in a porcine 
model. To test transgene expression after electroporation, we exam-
ined LacZ transgene-driven β-galactosidase expression. Histological 
analyses of transfected tissues (Figure 6a) demonstrated positive 
β-galactosidase expression in all test tissues with all controls nega-
tive for β-galactosidase expression. Importantly, the visual expres-
sion profile of pEEV lacZ was more abundant in comparison to the 
standard pCMV plasmid.
We again utilized the LacZ as a reporter transgene to compare 
the amount of gene expression induced from plasmids after elec-
troporation, and to determine if the transgene expression was con-
sistent with β-galactosidase staining (Figure 6b). As observed in the 
mouse models, pEEV lacZ was expressed at a significantly higher 
level when compared to the standard pCMV lacZ. To investigate the 
efficiency of transfection in our large animal model, we determined 
overall copy number (Figure 6c). While we observed that overall 
copy number was significantly lower for pEEV when compared to 
pCMV (similar to murine studies), we again observed that pEEV gave 
a significantly stronger expression profile when compared to pCMV. 
Taken together, these results demonstrate that pEEV can be used 
to effectively express exogenous genes within multiple tissues in a 
large animal model.
DISCUSSION
The current study provides evidence for significant enhance-
ments in the potential for nonviral DNA vector systems. Clinically, 
non–virus-mediated transgene expression has received increased 
attention because it is relatively safe, simple, and inexpensive 
compared to the administration of viral vectors, which are associ-
ated with the induction of neutralizing antibodies and cytotoxic-
ity.7,8 Electroporation is considered as a very useful tool for gene 
Figure 2 β-galactosidase expression in murine tissue. (a) Copy numbers 
of lacZ transgene ascertained by quantitative polymerase chain 
reaction (PCR) in murine tissue. Bar graph showing absolute copy 
number of the lacz transgene per nanogram of genomic DNA 2 days 
after electroporation obtained from MF1-nu/nu mouse tissue. All gDNA 
samples were normalized to 100 ng of DNA prior to PCR. Each individual 
sample was analyzed in triplicate for each quantiative PCR (qPCR). 
qPCR values are means ± standard error of the mean (SEM) of triplicate 
measurements. A comparison of enhanced expression vector (pEEV) 
(light gray bars) and pCMV (dark gray bars) samples were performed. 
***P < 0.0001. (b) Evaluation of lacZ mRNA transcript expression by qRT-
PCR in murine tissue. Bar graph presenting the relative expression of 
the lacZ mRNA 2 days after electroporation obtained from MF1-nu/nu 
mouse tissue. All qPCR data were normalized using 18S RNA as reference 
gene. Relative expression levels are plotted as means ± SEM of triplicate 
measurements. pEEV (light gray bars) and pCMV (dark gray bars). pEEV 
lacZ expressed was significantly higher than pCMV lacZ. ***P < 0.0001.
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Figure 3 Cytoplasmic expression of enhanced expression vector (pEEV) 
luciferase. Luciferase reporter assay to verify activity of plasmid in a 
nuclear free preparation. Relative luciferase expression was used as an 
indicator of expression and values are plotted as means ± standard error 
of the mean of triplicate measurements. Only pEEV luciferase expression 
was detected.
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Figure 4 Antitumor effects of nontherapeutic plasmid. (a) Tumor growth curve of CT26 tumors treated with pCMV backbone, pCMV lacZ, 
enhanced expression vector (pEEV) backbone, pEEV lacZ, and an untreated tumor growing on Balb/c mice (n = 6 per group) is presented as 
tumor diameter measured. Tumor volume was calculated as previously described. Data presented are means ± SEM of six individual tumors. 
*Compared to the untreated group and pEEV lacZ, *P < 0.05. (b) Representative Kaplan–Meier survival curve. The respective survival cure of the 
CT26-treated tumors growing on Balb/c mice (n = 6 per group). The pEEV lacZ-treated mice survived longer than any other group P < 0.05 versus 
the untreated tumor. The pEEV lacZ group survived 4 days longer than the pEEV backbone. (c) Oncolytic activity of pEEV lacZ in murine muscle. 
In vivo intramuscular plasmid delivery. In vivo muscle transfection by electroporation was demonstrated by luciferase activity, analyzed daily 
postintramuscular pCMVluc and pEEVluc, plasmid transfection via electroporation and subsequent gene expression was assessed using whole 
body imaging of luciferase expression. pCMV expression peaked day 2 in both C57BL/6J (C) and MF1-nu/nu mice (D) and pEEV peaked day 7 in 
both MF1-nu/nu (A) and C57BL/6J mice (B). No detection of pEEVluc was detected by day 9. (E) Bioluminesence data plotted over time for pEEVluc-
treated MF1-nu/nu mice.
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therapies and has received a lot of attention in the development 
and improvement of electrogene transfer protocols. Studies have 
included modulating the electric pulse, electrodes, extracellular 
matrix, which has an effect on transfection efficiency, and expres-
sion of the delivered gene.22,24,25,31,32 Others have modulated the 
size of the plasmid being delivered and used plasmid types such as 
minicircle plasmid.33 We have incorporated elements of a virus and 
nuclear localization sequence to allow for an enhanced expression 
of the gene of interest.
We have shown that a DNA-based pEEV has improved expres-
sion capabilities across a range of tissue histologies over standard 
nonviral DNA vectors. pEEV was developed utilizing the SFV rep-
licase, which allows for high levels of cytoplasmic expression and 
thereby overcoming the requirement and rate-limiting step for all 
plasmid copies to enter the nucleus in order for mRNA transcrip-
tion to occur. In the present study, we evaluated our pEEV construct 
and demonstrated its superior efficacy using reporter gene analysis 
while comparing findings to a standard plasmid. pEEV delivered via 
electroporation led to rapid mRNA expression in cancer cells. This 
approach was also found to have several advantages specifically 
for cancer therapy including: greatly improved and consistent gene 
expression and eventual direct oncolytic effect (cellular exhaustion) 
from continued mRNA production, which obviates the risk of long-
term exogenous gene expression.
The EEV construct contains a DNA sequence of 15 kb size. There 
was initial concern that the large size of pEEV would impact nega-
tively on its transfection efficacy after electroporation. Our data 
indicate that transfection levels for pEEV, i.e., copies of plasmid DNA 
within the cell postelectroporation, were indeed lower in compari-
son to the standard pCMV plasmid, which was only 6.2 kb in size. 
However, previous studies have indicated that self-amplifying vec-
tors only need a single RNA copy to reach the cytoplasm, whereby 
they can generate high expression levels almost independent of 
initial transfection and transcription efficiency. Indeed, although 
we observed overall lower transfection rates of pEEV, when com-
pared to the standard pCMV plasmid, this did not, however, result in 
a proportional decrease in mRNA expression levels within a nuclear 
free lysate. Significantly, mRNA expression levels were in fact four- 
to fivefold higher in pEEV-transfected cells, when compared to the 
more efficiently transfected standard commercial pCMV.
Targeting tumors with oncolytic viruses has demonstrated a 
promising approach for cancer treatment. These are modified or 
naturally oncotropic viruses, which selectively replicate in malignant 
tumor cells and finally destroy them via oncolysis, but this approach 
also encounters similar disadvantages as other viral therapies. 
Alphaviruses, like SFV, have also been successfully used as oncolytic 
agents in several preclinical models of cancer. They are enveloped 
viruses containing a single positive strand RNA genome which, after, 
can replicate in the cytoplasm. The SFV system is suicidal and are 
characterized by their high expression levels. This process induces a 
strong cytopathic effect that leads to cell death by apoptosis. Taking 
these characteristics into account, we incorporated these elements 
from the SFV to develop the pEEV. We demonstrated cytoplasmic 
expression of pEEV and wanted to further characterize if pEEV had 
oncolytic effects like its viral parent. The stable presence and expres-
sion of plasmid DNA vectors in muscle have been demonstrated in 
several studies. We observed that in vivo muscle expression peaked 
on day 6 for pEEV transfection with expression levels declining and 
undetectable by day 9. This cellular oncolysis feature of pEEV could 
benefit cancer gene therapy applications such as by acting as a 
safety feature for over or continuous expression. Antitumor effects 
of pEEV were demonstrated by the delay in growth and increased 
survival of a nontherapeutic pEEV-treated CT26 tumor model. This 
oncolytic characteristic and the high expression level trait of pEEV 
highlight the potential of this vector as an anticancer vector.
The electroporation gene transfer protocol appears to be safe 
and nontoxic. All mice remained healthy throughout the course of 
the experiments, and there were no treatment-related deaths. This 
suggests that electroporation of solid tumours is not traumatic and 
that the levels produced by the pEEV did not induce systemic toxic-
ity. Other studies have observed similar safe and nontoxic effects 
of electrogene transfer.34,35 The ultimate aim of any preclinical gene 
therapy study is to translate findings to the clinic. The safety of elec-
troporation as part of treatment in human patients has been vali-
dated in several studies of electrochemotherapy and electrogene 
transfer.21,36
We wanted to assess the expression levels of pEEV; however, effi-
cacy in mouse models does not necessarily translate into patients. 
While our pEEV preclinical studies in mice revealed very promising 
results, we proceeded to validate the approach in the larger pig 
in vivo model. Pigs are an excellent larger animal model to study 
human physiology/disease due to many similar attributes including 
anatomy, genetics, and physiology. Indeed, pig models have been 
used to evaluate the safety and efficacy of gene therapy; however, 
studies have yielded varying results with regards to detectable lev-
els of gene expression. Employing the EndoVe, a novel endoscopic 
electroporation device, we were able to demonstrate the reliability 
of the pEEV to express the β-galactosidase reporter gene across a 
range of intraluminal porcine tissue types. The high levels of pEEV 
reporter gene expression in this pig study indicates the potential 
utility of pEEV in the clinic and as a therapeutic tool in gene therapy. 
The data also clearly reveal the lack of consistent expression for the 
pCMV vector when translated from murine to porcine tissue; in con-
trast, consistent levels of reporter gene expression were detected 
across all tissue types for the pEEV plasmid.
A growing number of clinical studies have established that elec-
troporation is safe and effective in delivering plasmid DNA and 
chemotherapeutic drugs efficiently.20,21 In this study, we used a 
Figure 5 Apoptosis in tumors. Apoptotic dead was evaluated using 
terminal deoxynucleotidyl transferase–mediated deoxyuridine 
triphosphate nick-end labeling (TUNEL) staining on CT26 tumor model 
grown on Balb/c mice. Tumors were removed from mice at various time 
points following treatment; paraffin-embedded and stained sections 
were examined microscopically. TUNEL stained for evidence of apoptotic 
cells indicate significant apoptosis in the tumor treated with pEEV lacZ 
and pEEV backbone but not from untreated groups.
EEV-LacZ
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CMV-LacZ
24 hours 48 hours 72 hours
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previously reported safe and nontoxic parameters of electropora-
tion-mediated transfer of the DNA plasmid to deliver pEEV in vivo. 
We found that the combination of an already established electro-
poration methodology and pEEV allows for an extremely reliable 
means of gene delivery and expression.
Taken together, our results clearly demonstrate the potential of 
pEEV as a safe DNA vector with superior expression capabilities 
over standard available vectors. This vector, in combination with 
electroporation, allows for a safe and minimally invasive method of 
delivery. This study suggests that the pEEV expressing a therapeutic 
gene may have potential for clinical development with high detect-
able levels of expression.
MATeRIAlS AND MeTHODS
Animals
Female Balb/c, C57BL/6, and MF1-nu/nu mice (6–8 weeks) were obtained 
from Harlan Laboratories (Oxfordshire, England). Female pigs (Landrace) 
were obtained from Teagasc, Moorepark, Ireland, and the pigs used were 
25–30 kg. Standard laboratory food and water were provided ad libitum.
Ethics statement
All animal husbandry and experimental procedures were approved by 
the University College Cork Animal Experimentation Ethics Committee 
and carried out under licenses issued by the Department of Health, 
Ireland as directed by the Cruelty to Animals Act Ireland and EU Statutory 
Instructions.
Figure 6 β-Galactosidase expression in porcine tissue. (a) Representative image of β-galactosidase staining in porcine tissues. β-Galactosidase 
expression significantly increased in enhanced expression vector (pEEV) lacZ in all tissues been examined. (b) Evaluation of lacZ mRNA transcript 
expression by qRT-PCR in porcine tissue. Bar graph presenting the relative expression of the lacZ mRNA 2 days after electroporation. All qPCR data 
were normalized using 18S RNA as reference gene. Relative expression levels are plotted as means ± standard error of the mean (SEM) of triplicate 
measurements. pEEV (light gray bars) and pCMV (dark gray bars). pEEV lacZ expressed was significantly higher than pCMV lacZ. (c) Copy numbers of 
lacZ transgene ascertained by quantitative PCR in porcine tissue. Bar graph showing absolute copy number of the lacz transgene per nanogram of 
genomic DNAs 2 days after electroporation. All gDNA samples were normalized to 100 ng of DNA prior to PCR. Each individual sample was analyzed in 
triplicate for each qPCR. qPCR values are means ± SEM of triplicate measurements. A comparison of pEEV (light gray bars) and pCMV (dark gray bars) 
samples were performed.
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Cell tissue culture
Tumor cell lines were obtained from the American Type Culture Collection 
(Manassas, VA). The murine colon adenocarcinoma, CT26 cell line was cul-
tured with Dulbecco’s modified Eagle’s medium (Sigma, Wicklow, Ireland), 
supplemented with 10% v/v fetal calf serum and 300 µg/ml L-glutamine. The 
human adenocarcinoma, OE19 cell line was cultured in RPMI-1640 (Sigma) 
supplemented with 10% v/v fetal calf serum and 300 µg/ml L-glutamine. 
Cells were maintained in logarithmic phase growth at 37 °C in a humidified 
atmosphere supplemented with 5% CO2.
Tumor induction
For routine tumor induction, 1 × 106 CT26 or OE19 tumor cells, suspended in 
200 µl of serum-free Dulbecco’s modified Eagle’s media were injected sub-
cutaneously into the flank Balb/C (CT26) or MF1-nu/nu mice (OE19). Tumors 
were allowed to develop and size was monitored by measurements in two 
dimensions using vernier calipers. Tumor volume was calculated according 
to the formula V = ab2π/6, where a is the longest diameter of the tumor and 
b is the longest diameter perpendicular to diameter a. From these volumes, 
tumor growth curves were constructed. Mice were euthanized when tumor 
volume reached 1.7 cm3 as approved by the University College Cork Animal 
Experimentation Ethics Committee.
Plasmids
For plasmid transfection, a pCMV-lacz plasmid (Plasmid factory) was used 
encoding a β-galactosidase protein (LacZ) gene under the control of a CMV 
promoter. The EEV plasmid was created by incorporating a SFV DNA replicase 
sequence (kindly donated by Prof Greg Atkins, Virus Group, Department of 
Microbiology, School of Genetics and Microbiology, Trinity College Dublin). 
A nuclear localization sequence was also incorporated to allow for more effi-
cient nuclear targeting of the pEEV plasmid (Figure 1). The pMG plasmid was 
purchased from InvivoGen  (Toulouse, France) (Supplementary Figure S1). 
Plasmids were propagated in Escherichia coli strain Top10 and purified on 
endotoxin-free Qiagen-tip 500 columns (Qiagen, Manchester, UK).
DNA transfection and in vivo electroporation
A range of tissues were transfected including a subcutaneous tumor (Oe19) 
and healthy tissue (muscle, liver, and spleen). Tissues were injected with 50 µg 
of the respective plasmid and surgically removed 48 hours following in vivo 
transfection by electroporation. The number of plasmid DNA and LacZ expres-
sion was then determined. Procedures were carried out under general anesthe-
sia, using intraperitoneal administration of 200 µg xylazine and 2 mg ketamine. 
The skin overlying the flank muscle and tumor was shaved and a midline lapa-
rotomy was used to expose the liver and spleen. Fifty micrograms of plasmid 
DNA in 50 µl sterile injectable phosphate-buffered saline (PBS) was injected 
into the tumor, muscle, liver, and spleen. Parallel plate electrodes,37 with an 
adjustable separation setting, were inserted on either side of the marked DNA 
injection point and electroporation pulses delivered within 1 minute of DNA 
injection. For this study, plate electrodes were fixed at 1 cm apart.
Pigs were sedated with 400 mg of ketamine and 80 mg of xylazine 
injected into the cervical musculature followed by 150 mg/3 ml intravenous 
administration of the cardioprotective agent amiodarone hydrochloride. 
Anesthesia was maintained using a 200 mg ketamine and 10 mg midazolam 
solution. Surgical access to muscle tissue was obtained by making a 6 cm 
linear incision over the appropriate flank using bipolar diathermy. Open sur-
gical access to the liver and spleen was obtained through a midline laparot-
omy incision. Access to the gastrointestinal tissues—esophagus and rectum 
was achieved using the EndoVe device (Cork Cancer Research Centre, Cork, 
Ireland). Fifty micrograms of plasmid DNA in 50 µl sterile injectable PBS was 
injected directly into the target tissues. Electric pulses were delivered using 
the EndoVe. In vivo electroporation parameters were a single 1,200 V/cm, 
100 μsec pulse followed after 1 second by a train of eight 120 V/cm, 20 msec 
pulses at 1 Hz administered in sequence using the E.Pore Gx (Cork Cancer 
Research Centre) electroporation generator.
Histological evaluation
Animals were sacrificed; tissues extracted and washed three times in PBS. 
β-galactosidase staining was performed on tissue using the β-galactosidase 
reporter gene staining kit (Sigma). Tissues were fixed in a 1X fixation solution 
for 30 minutes. After fixation, the tissues were rinsed three times in PBS and 
incubated for 24 hours in X-gal staining solution. Tissues from each animal 
were processed separately. At the end of the incubation period, tissues were 
rinsed with PBS. Tissues were embedded in paraffin and serial sections were 
cut at 5 µm and mounted on slides. Hematoxylin and eosin staining was per-
formed for both murine and porcine samples to assess for tissue damage.
RNA isolation and reverse transcriptase reaction
Frozen tissue samples preserved in RNAlater were homogenized in the pres-
ence of Trizol (Sigma), and total RNA was isolated according to manufacturer’s 
instructions. Each sample was treated with DNase I (Ambion, Cambridgeshire, 
UK) to eliminate any possible DNA contamination and subsequently tested 
for presence of DNA using PCR amplification without the reverse transcrip-
tion step. Total RNA concentration was determined from spectrophotometric 
optical density measurement (260 and 280 nm). For each sample tested, the 
ratio between the spectrophotometric readings at 260 and 280 nm (OD260/
OD280) was used to provide an estimate of the purity of the nucleic acid, 
and the ratio in all samples ranged between 1.7 and 2.0. Reverse transcrip-
tase reactions were carried out using the omniscript reverse transcription 
kit (Qiagen) and Oligo(dt)15 primer (Promega, Hampshire, UK). Each reaction 
tube contained 1 µg of DNAse-treated total RNA in a volume of 20 µl.
Genomic DNA extraction
Genomic DNA was prepared according to manufacturer’s protocol using the 
genElute mammalian genomic DNA miniprep kit (Sigma-Aldrich, Wicklow, 
Ireland). Final DNA concentration was determined with the use of spectro-
photometric measurement.
Real-time PCR
Real-time PCR amplification was performed with the lightCycler fastStart DNA 
master SYBR green I (Roche, Hertfordshire, UK) at final concentrations of 3 
mmol/l magnesium, 0.5 µmol/l of each primer, and 1X LightCycler FastStart 
DNA master SYBR green I. The final volume of each reaction was 20 µl, contain-
ing 50 ng of reverse transcription product as template. The amplification pro-
gram started with 1 cycle at 95 °C for 10 minutes, followed by 38 cycles at 95 °C 
for 15 seconds, 60 °C for 20 seconds, and 72 °C for 20 seconds. The program 
ended with 1 cycle at 72 °C for 15 minutes. The following primers for lacZf and 
lacZr were designed to amplify 185 bp, and their sequences are as follows: lacZf: 
5′-GCG TGG ATG AAG ACC AGC-3′, lacZr: 5′-CGA AGC CGC CCT GTA AAC-3′. 
The housekeeping 18s rRNA was used as an internal control;38 18srRNAf: 5′-
TTG ACG GAA GGG CAC CAC CAG-3′, 18srRNAr: 5′-GCA CCA CCA CCC ACG 
GAA TCG-3′. For genomic PCR, all samples were normalized to 100 ng/ μl of 
gDNA. Hundred nanograms of DNA were used with similar PCR mixture con-
tents and cycling parameters (40 cycles). LacZgf: 5′-GAC GTC TCG TTG CTG CAT 
AA-3′, LacZgr: 5′-CAG CAG CAG ACC ATT TTC AA-3′.
Quantification of apoptosis by TUNEL
To assess whether pEEV vector could also induce apoptotic death in vivo, 
pEEV, pEEV lacZ, and pCMV lacZ was delivered into CT26 tumors via elec-
troporation. Evaluation of the tumors for TUNEL (Roche) staining (which 
marks apoptotic cells) was utilized. Balb/C mice bearing CT26 tumors were 
subcutaneously injected with 50 μg of plasmid DNA followed by electro-
poration. Mice were culled on 24, 48, and 72 hours posttreatment and 
tumors were removed for detecting in situ apoptosis by TUNEL assay. The 
TUNEL-positive cells were stained brown. TUNEL staining of tissues was 
performed according to the manufacturer’s protocol with minor modifica-
tions. In brief, processed tissues were embedded in paraffin, cut into 5 µm 
thick sections, placed on superfrost plus slides, and adhered by heating 
at 37 °C for 12 hours. Slides were deparaffinized and rehydrated by suc-
cessive incubations in xylene, absolute ethanol, and 70% ethanol. Nuclei 
in tissue sections were stripped of protein by treating with proteinase k 
(20 µg/ml) for 20 minutes followed by four successive washes with PBS. 
Slides were incubated with TUNEL reaction mixture at 37 °C for 60 min-
utes in a humidified atmosphere followed by three successive washes 
with PBS. Sections were incubated with horse-radish peroxidise (Roche) 
for 30 minutes, rinsed in PBS, and stained with DAB substrate kit (Dako, 
Dublin, Ireland) according to manufactures’ recommendations. A positive 
control was established by incubating tissue section with DNase (1 µg/
ml) after deproteination and peroxidase inactivation. Intense staining was 
observed in cells from the Dnase-treated sections. A negative control was 
established by incubating tissue sample with DAB after deproteination 
and peroxidase inactivation. No staining was observed.
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Bioluminescence imaging
Bioluminescence imaging was performed as previously described,14 with 
an IVIS 100 charge-coupled device imaging system (Xenogen, Alameda, 
CA). Bioluminescent signals were quantified by the creation of regions of 
interest. To standardize the data, light emission from the same surface area 
(regions of interest) was quantified for each transfected animal. In addi-
tion, background light emission, taken from regions of interest created on 
untransfected control animals, was subtracted from transfected test animals. 
Imaging data were analyzed and quantified with Living Image Software 2.50 
(Xenogen) and expressed as photons/second/cm2.
Cytoplasmic expression assay
Cytoplasmic expression was assessed for both plasmid systems using a 
nuclear free cytoplasmic preparation. The standard commercial rabbit retic-
ulocyte lysate cell-free system (Promega) was used to characterize transla-
tion products from mRNA encoding T7 RNA polymerase. This preparation 
consisted of a cytoplasmic free of nuclear material lysate and mRNA encod-
ing T7 RNA polymerase. Each plasmid was incubated at 30 °C for a period 
of 2 hours. Luciferase expression was detected using the IVIS 100 charge-
coupled device imaging system (Xenogen). pCMV was added as a control 
plasmid to demonstrate the efficiency of pEEV expression in cytoplasm lys-
tae when there is a mRNA encoding T7 RNA polymerase present and the 
requirement of the T7 promoter.
Statistical analysis
Experimental results were plotted and analyzed for significance with Prism 
4 software (GraphPad software, La Jolla, CA). P < 0.05 was considered 
significant.
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